› 3rq7

X-ray diffraction
1.55Å resolution

Polo-like kinase 1 Polo box domain in complex with a C6H5(CH2)8-derivatized peptide inhibitor

Released:
DOI: 10.2210/pdb3rq7/pdb
PDB entry 3rq7 coloured by chain, front view.
PDB entry 3rq7 coloured by chain, side view.
PDB entry 3rq7 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel.
Liu F, Park JE, Qian WJ, Lim D, Gräber M, Berg T, Yaffe MB, Lee KS, Burke TR
Nat Chem Biol 7 595-601 (2011)
PMID: 21765407

Function and Biology Details

Reaction catalysed: 
ATP + a protein = ADP + a phosphoprotein
Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
hetero dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-156764 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Serine/threonine-protein kinase PLK1 Chain: A
Molecule details ›
Chain: A
Length: 237 amino acids
Theoretical weight: 27.29 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P53350 (Residues: 371-603; Coverage: 39%)
Gene names: PLK, PLK1
Sequence domains: POLO box duplicated region
Structure domains: POLO box domain
C6H5(CH2)8-derivatized peptide inhibitor Chain: B
Molecule details ›
Chain: B
Length: 7 amino acids
Theoretical weight: 846 Da
Source organism: Homo sapiens
Expression system: Not provided

Ligands and Environments

No bound ligands
1 modified residue:
Ligand TPO 1 x TPO

Experiments and Validation Details

Entry percentile scores
X-ray source: RIGAKU MICROMAX-007 HF
Spacegroup: P21
Unit cell:
a: 35.337Å b: 51.21Å c: 57.963Å
α: 90° β: 101° γ: 90°
R-values:
R R work R free
0.154 0.152 0.19
Expression systems:
  • Escherichia coli
  • Not provided

Quick links

Citations

7 review citations

Understanding the Polo Kinase machine.
Archambault et al. (2015)
6 more

24 mentions without citation

Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.
Lee et al. (2015)
23 more